1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Valneva Rebounds From 2022 Setbacks With Pivotal Success For Chikungunya Jab

 
• By Ayisha Sharma

The French firm’s vaccine candidate, VLA1553, has passed a Phase III milestone for the mosquito-borne disease – which has no approved options – as it bounces back from a year full of COVID-19-related disappointments.  

mosquito on skin
The Mosquitoes That Spread Chikungunya Are Moving Into New Areas • Source: Shutterstock
Key Takeaways:

  • VLA1553 produced protective antibody levels in 99% of subjects after a single dose.

Valneva SE’s chikungunya vaccine candidate, VLA1553, has succeeded in a Phase III trial, boding well for filings submitted in the US and Canada as the firm leaves behind its COVID-19 related woes in 2022.

Chikungunya is a mosquito-borne viral disease endemic in some parts of Africa, Asia and the Americas. Symptoms include fever, headaches,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

More from R&D